Data mining of external application of traditional Chinese medicine for malignant ascites based on medication rules and factor analysis
WANG Gui1,2 YU Ran1,2 LOU Yanni2 LI Yuan2 JIA Liqun2
1.Graduate School, Beijing University of Chinese Medicine, Beijing 100029, China;
2.Department of Oncology of Integrative Chinese and Western Medicine, China-Japan Friendship Hospital, Beijing 100029, China
Abstract:Objective To explore the medication rules of external treatment of traditional Chinese medicine for malignant ascites. Methods Taking “malignant ascites” and “external treatment of traditional Chinese medicine” as the theme words, comprehensive search of the database of CNKI, Wanfang and VIP from its inception to June 2019 was conducted. The formulas of external treatment of traditional Chinese medicine for malignant ascites were included and the association rule, clustering and factor analysis were carried out. Results A total of 73 prescriptions meeting the inclusion criteria were collected, among which 20 high-frequency drugs with frequency ≥ 10 were used, including Cinnamon (35 times), Astragalus (32 times), Kansui (31 times), Petunia (28 times), Poria (25 times), Curcuma (22 times) were the most commonly used, most of which were warm drugs and bitter drugs, mostly attributed to spleen and lung meridian. Association rule analysis found that there were 8 drug pair combinations with support > 16% and 17 drug pair combinations with promotion > 3. Cluster analysis can be classified into 4 categories, and factor analysis extracted 10 common factors. Conclusion The principle of external treatment of malignant ascites is mainly “warming yang and benefiting qi”, “benefiting water infiltration and dampness”, and “promoting blood circulation and removing blood stasis”.
王贵1,2 于然1,2 娄彦妮2 李园2 贾立群2. 基于关联规则和因子分析挖掘中医外治恶性腹水用药配伍规律[J]. 中国医药导报, 2020, 17(6): 157-160,164.
WANG Gui1,2 YU Ran1,2 LOU Yanni2 LI Yuan2 JIA Liqun2. Data mining of external application of traditional Chinese medicine for malignant ascites based on medication rules and factor analysis. 中国医药导报, 2020, 17(6): 157-160,164.